The ultimate goal of the experiments conducted in the realm of this work was to design, synthesize, characterize some novel heterocyclic compounds comprising of 4-arylpiperazine/ aniline moiety linked to a terminal cyclic amide through a spacer followed by their biological evaluation and molecular modeling studies as anti-convulsants and evaluation of their interactions with 5-HT1A and 5-HT2A receptor subtypes as agonist/antagonist through validated in vivo behavioral models.